Evidence map›Paper›PMID 36389826›Full record

ArticleFrontiers in immunology2022

Clinical features and prognosis of MPO-ANCA and anti-GBM double-seropositive patients.

Xueling Hu, Chanjuan Shen, Ting Meng, Joshua D Ooi, Peter J Eggenhuizen, Ya-Ou Zhou, Hui Luo, Jin-Biao Chen, Wei Lin, Yizi Gong and 6 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Cell-Free DNA-Based Theranostics for Inflammatory Disorders.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Xueling HuDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, China.
Chanjuan ShenDepartment of Hematology, The Affiliated Zhuzhou Hospital of Xiangya Medical College, Central South University, Zhuzhou, China.
Ting MengDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, China.
Joshua D OoiDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, China.
Peter J EggenhuizenCentre for Inflammatory Diseases, Department of Medicine, Monash Medical Centre, Monash University, Clayton, VIC, Australia.
Ya-Ou ZhouDepartment of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, China.
Hui LuoDepartment of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, China.
Jin-Biao ChenDepartment of Medical Records and Information, Xiangya Hospital, Central South University, Changsha, China.
Wei LinDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, China.
Yizi GongDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, China.
Qi XiongDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, China.
Jia XuDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, China.
Ning LiuDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, China.
Xiangcheng XiaoDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, China.
Rong TangDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, China.
Yong ZhongDepartment of Nephrology, Xiangya Hospital, Central South University, Changsha, China.
Central South University · CNMonash Medical Centre · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Several lines of evidence implicate that there are distinct differences between patients with myeloperoxidase (MPO)-antineutrophil cytoplasmic antibody (ANCA) and anti-glomerular basement membrane (GBM) antibody double-seropositive patients (DPPs) and single-positive patients. Hence, we conducted a retrospective study from a single center in China to analyze the clinical and pathological features, and prognosis of DPPs. Methods: 109 patients with MPO-ANCA-associated vasculitis (MPO-AAV), 20 DPPs and 23 patients diagnosed with anti-GBM disease from a large center in China were included in this study. The ratio of patients with renal biopsy in three groups were 100%, 50% and 100%, respectively. Their clinical and pathological characteristics, and outcomes were analyzed. The intensity of immune deposits in the kidney at diagnosis was detected by immunofluorescence (IF). Furthermore, multivariate Cox hazard model analysis was used to assess the clinical and histological predictors of end-stage renal disease (ESRD) and death for DPPs. Results: In our study, we found that patients in the DPPs group were older than the other two groups ( Conclusion: In summary, compared with anti-GBM disease, DPPs tended to involve multi-organ damage rather than limited to the kidney. It is highlighted that serologic DPPs have a worse renal and patient prognosis than MPO-AAV. Moreover, we found that the risk factors of renal survival of DPPs include low lymphocyte count, elevated serum creatinine and reduced eGFR, and serum creatinine can predict patient survival.

Indexed as

Anti-Glomerular Basement Membrane DiseaseAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisKidney Failure, ChronicAntibodies, Antineutrophil CytoplasmicAutoantibodiesCreatinineHumansPeroxidasePrognosisRetrospective StudiesAntibodies, Antineutrophil Cytoplasmicantiglomerular basement membrane antibodyAutoantibodiesCreatininePeroxidaseANCA-associated vasculitisanti-GBM diseasedouble positive vasculitismyeloperoxidaserenal survivalrisk factors

Identifiers

PMID36389826
PMCPMC9648717
OpenAlexW4307355925

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.